FNA250117P2500
- 0.00
- 0.000.00%
Paragon 28 Newsroom
Paragon 28 Is Maintained at Buy by Canaccord Genuity
Paragon 28 Price Target Cut to $15.00/Share From $17.00 by Canaccord Genuity
Piper Sandler Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Cuts Target Price to $15
BofA Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
Paragon 28 Analyst Ratings
Needham Maintains Paragon 28(FNA.US) With Buy Rating, Raises Target Price to $13
JMP Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $20
Buy Rating on Paragon 28: Strong Financial Performance, Strategic Initiatives, and Niche Market Success
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Paragon 28 (FNA)
Paragon 28 Analyst Ratings
Needham Maintains Buy on Paragon 28, Lowers Price Target to $11
Buy Rating Affirmed for Paragon 28 Amid Strong Financial Performance and Strategic Growth
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $17
J.P. Morgan Securities: Maintaining the Paragon 28 (FNA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $23.00 to $20.00.
Paragon 28 Analyst Ratings
JMP Securities Maintains Market Outperform on Paragon 28, Lowers Price Target to $20
Paragon 28 (FNA) Gets a Buy From Piper Sandler